Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

Impact of Consolidative Cellular Therapy with DLI or Second Transplant in Patients with AML Who Achieve Complete Remission Following Post-Transplant Relapse

H. Moses Murdock, Haesook T. Kim, Katie Maurer, Amar H. Kelkar, Roman M. Shapiro, Mahasweta Gooptu, Rizwan Romee, Corey S. Cutler, John Koreth, Jerome Ritz, Joseph H. Antin, Vincent T. Ho, Sarah Nikiforow, Catherine J. Wu, Robert J. Soiffer

Blood (2024) 144 (Supplement 1): 3538.

https://doi.org/10.1182/blood-2024-204343

Published: 2024

Journal Articles

Feasibility, Safety and Efficacy of Oral Maintenance Therapy with Venetoclax Plus Decitabine/Cedazuridine after Venetoclax Plus FluBu2 for High Risk MDS/AML Undergoing RIC Allo-HCT

Jacqueline S. Garcia, Haesook T. Kim, Jennifer Brock, H. Moses Murdock, Mahasweta Gooptu, Vincent T. Ho, Roman M. Shapiro, Christopher J. Gibson, Amar H. Kelkar, Corey S. Cutler, Denbaa Bat-Erdene, Jeremy Ryan, Anna Bosch-Vilaseca, Anthony G. Letai, Jerome Ritz, Coleman Lindsley, Robert J. Soiffer, Joseph Antin

Blood (2024) 144 (Supplement 1): 1045.

https://doi.org/10.1182/blood-2024-194170

Published: 2024

Journal Articles

Superiority of Post-Transplant Cyclophosphamide-Based Graft Versus Host Disease (GvHD) Prophylaxis in Patients 70 Years and Older: A BMT CTN 1703 Post-Hoc Analysis

Blood (2024) 144 (Supplement 1): 1042.

https://doi.org/10.1182/blood-2024-193827

Published: 2024

Journal Articles

Effects of GvHD Prophylaxis with Post-Transplant Cyclophosphamide on Immune Reconstitution and TCR Repertoire after Haploidentical and HLA-Matched Transplantation Compared to Prophylaxis with Calcineurin Inhibitor Plus Methotrexate in HLA-Matched Transplantation

Michela Ansuinelli, Haesook T. Kim, Carol G. Reynolds, Francesco Malfona, Shuntaro Ikegawa, Rakuyo Tamada, Roman M. Shapiro, Mahasweta Gooptu, Rizwan Romee, Sarah Nikiforow, John Koreth, Vincent T. Ho, Corey S. Cutler, Joseph H. Antin, Leslie Kean, Robert J. Soiffer, Jerome Ritz

Blood (2024) 144 (Supplement 1): 1041.

https://doi.org/10.1182/blood-2024-201835

Published: 2024

Journal Articles

OPTIMIZE: A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide As GVHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Jeffery J. Auletta, Steven M. Devine, Heather E. Stefanski, Stephen R. Spellman, Todd E. Defor, Brent R. Logan, Brandan J. Butler, Mahasweta Gooptu, Brian C. Shaffer, Antonio M. Jimenez Jimenez, Sameem Abedin, Dipenkumar Modi, MHD Monzr M. Al Malki, Rachel J. Cook

Blood (2024) 144 (Supplement 1): 3514.1.

https://doi.org/10.1182/blood-2024-198252

Published: 2024

Journal Articles

Heterogeneity of PD-1 + regulatory T Cells after Low-Dose IL-2 Therapy for Patients with Chronic Graft-Versus-Host Disease

Blood (2024) 144 (Supplement 1): 379.

https://doi.org/10.1182/blood-2024-200128

Published: 2024

Journal Articles

BK Virus Reactivation and Disease after Allogeneic Hematopoietic-Cell Transplantation: A Natural History Study

Blood (2024) 144 (Supplement 1): 3500.

https://doi.org/10.1182/blood-2024-199776

Published: 2024

Journal Articles

Induction of Graft-Versus-Leukemia Effect with Treg-Depleted DLI Plus Ipilimumab for Myeloid Disease Relapse after HLA-Matched Transplant

Roman M. Shapiro, Haesook T. Kim, William H Terral, Vincent T. Ho, Mahasweta Gooptu, Rizwan Romee, Christopher J. Gibson, Amar H. Kelkar, Corey S. Cutler, Joseph H. Antin, Katie Maurer, Catherine J. Wu, Robert Zeiser, Jerome Ritz, Robert J. Soiffer, Sarah Nikiforow, John Koreth

Blood (2024) 144 (Supplement 1): 4833.

https://doi.org/10.1182/blood-2024-194102

Published: 2024

Journal Articles

Early CMV Viral Load Burden Predicts Late Clinically Significant CMV Infections in Patients Receiving Ptcy-Based Hematopoietic Cell Transplantation

Jessica S. Little, Kyle Hebert, Donna S. Neuberg, Sarah Nikiforow, Mahasweta Gooptu, Roman M. Shapiro, John Koreth, Joseph H. Antin, Corey S. Cutler, Robert J. Soiffer, Jerome Ritz, Rizwan Romee, Vincent T. Ho, Nicolas C Issa, Lindsey R. Baden, Remy Dulery, Susan E Prockop

Blood (2024) 144 (Supplement 1): 4885.

https://doi.org/10.1182/blood-2024-205169

Published: 2024

Journal Articles

Redefining Clinical Response Criteria in Myelodysplastic Syndromes to Better Forecast Post-Transplant Outcomes

Blood (2024) 144 (Supplement 1): 4938.

https://doi.org/10.1182/blood-2024-209087

Published: 2024

Journal Articles

Expression of HLA-B*35 Is Associated with an Increased Risk of CMV Viremia and Clinically Significant CMV Infection in Patients Receiving Ptcy-Based Hematopoietic Cell Transplantation

Blood (2024) 144 (Supplement 1): 4866.

https://doi.org/10.1182/blood-2024-205070

Published: 2024

Journal Articles

Post-Transplant T Cell Clonotype Diversity Is Associated with Survival in Patients with TP53-Mutated Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 2176.

https://doi.org/10.1182/blood-2023-181863

Published: 2023

Journal Articles

Effective Prevention of Steroid-Requiring Chronic Graft-Vs.-Host Disease with B Cell Depletion: A Randomized, Placebo-Controlled Trial

Blood (2023) 142 (Supplement 1): 649.

https://doi.org/10.1182/blood-2023-180142

Published: 2023

Journal Articles

Impact of Clinical and Genetic Factors on Myelofibrosis Outcomes after Allogeneic Transplantation

Mahasweta Gooptu, Haesook T. Kim, Kaina Chen, Ann Mullally, Joseph Antin, Corey Cutler, Amar H Kelkar, John Koreth, Roman M. Shapiro, Robert J. Soiffer, Daniel J. DeAngelo, Jacqueline S. Garcia, Marlise R. Luskin, Richard M Stone, Martha Wadleigh, Eric S. Winer, R. Coleman Lindsley, Vincent Ho

Blood (2023) 142 (Supplement 1): 4978.

https://doi.org/10.1182/blood-2023-178684

Published: 2023

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults with Acute Lymphoblastic Leukemia - Retrospective Dual-Center Study

Blood (2023) 142 (Supplement 1): 4979.

https://doi.org/10.1182/blood-2023-179962

Published: 2023

Journal Articles

A Simple Prediction Model of Outcomes after Allogeneic Hematopoietic Stem Cell Transplant (HCT) in Myelodysplastic Syndromes Using HCT-Comorbidity Index, Cytogenetic Risk, and Platelet Count

Blood (2023) 142 (Supplement 1): 2246.

https://doi.org/10.1182/blood-2023-185315

Published: 2023

Journal Articles

Post Allogeneic Stem Cell Transplant Outcomes Following Response to Hypomethylating Agent Therapy in Myelodysplastic Syndromes Are Predicted By Persistent International Prognostic Scoring System-Molecular Risk

Blood (2023) 142 (Supplement 1): 3618.

https://doi.org/10.1182/blood-2023-185220

Published: 2023

Journal Articles

Post-Transplant Cyclophosphamide Eliminates Disparity in GvHD-Free, Relapse-Free Survival and Overall Survival between 8/8 Matched and 7/8 Mismatched Unrelated Donor Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies

Jeffery J. Auletta, Monzr M. Al Malki, Todd DeFor, Brian C. Shaffer, Mahasweta Gooptu, Javier Bolanos-Meade, Ramzi Abboud, Adrienne D. Briggs, Farhad Khimani, Dipenkumar Modi, Richard Newcomb, Elizabeth J. Shpall, Caitrin Bupp, Stephen R. Spellman, Heather E. Stefanski, Antonio M. Jimenez Jimenez, Steven M. Devine

Blood (2023) 142 (Supplement 1): 780.

https://doi.org/10.1182/blood-2023-172722

Published: 2023

Journal Articles

Patient-Reported Outcomes of BMT CTN 1703: A Randomized Phase III Study for Gvhd Prophylaxis - a Quality of Life Evaluation

Blood (2023) 142 (Supplement 1): 897.

https://doi.org/10.1182/blood-2023-187859

Published: 2023

Journal Articles

Large-Scale Post-Transplant TCR Deep Sequencing Reveals a Major T Cell Diversity Bottleneck with Post-Transplant Cyclophosphamide with Implications for Both Efficacy and Toxicity: Results of the BMT CTN 1801 Study

Blood (2023) 142 (Supplement 1): 475.

https://doi.org/10.1182/blood-2023-188032

Published: 2023

NARROW

Impact of Consolidative Cellular Therapy with DLI or Second Transplant in Patients with AML Who Achieve Complete Remission Following Post-Transplant Relapse

Feasibility, Safety and Efficacy of Oral Maintenance Therapy with Venetoclax Plus Decitabine/Cedazuridine after Venetoclax Plus FluBu2 for High Risk MDS/AML Undergoing RIC Allo-HCT

Superiority of Post-Transplant Cyclophosphamide-Based Graft Versus Host Disease (GvHD) Prophylaxis in Patients 70 Years and Older: A BMT CTN 1703 Post-Hoc Analysis

Effects of GvHD Prophylaxis with Post-Transplant Cyclophosphamide on Immune Reconstitution and TCR Repertoire after Haploidentical and HLA-Matched Transplantation Compared to Prophylaxis with Calcineurin Inhibitor Plus Methotrexate in HLA-Matched Transplantation

OPTIMIZE: A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide As GVHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Heterogeneity of PD-1 + regulatory T Cells after Low-Dose IL-2 Therapy for Patients with Chronic Graft-Versus-Host Disease

BK Virus Reactivation and Disease after Allogeneic Hematopoietic-Cell Transplantation: A Natural History Study

Induction of Graft-Versus-Leukemia Effect with Treg-Depleted DLI Plus Ipilimumab for Myeloid Disease Relapse after HLA-Matched Transplant

Early CMV Viral Load Burden Predicts Late Clinically Significant CMV Infections in Patients Receiving Ptcy-Based Hematopoietic Cell Transplantation

Redefining Clinical Response Criteria in Myelodysplastic Syndromes to Better Forecast Post-Transplant Outcomes

Expression of HLA-B*35 Is Associated with an Increased Risk of CMV Viremia and Clinically Significant CMV Infection in Patients Receiving Ptcy-Based Hematopoietic Cell Transplantation

Post-Transplant T Cell Clonotype Diversity Is Associated with Survival in Patients with TP53-Mutated Acute Myeloid Leukemia

Effective Prevention of Steroid-Requiring Chronic Graft-Vs.-Host Disease with B Cell Depletion: A Randomized, Placebo-Controlled Trial

Impact of Clinical and Genetic Factors on Myelofibrosis Outcomes after Allogeneic Transplantation

Allogeneic Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults with Acute Lymphoblastic Leukemia - Retrospective Dual-Center Study

A Simple Prediction Model of Outcomes after Allogeneic Hematopoietic Stem Cell Transplant (HCT) in Myelodysplastic Syndromes Using HCT-Comorbidity Index, Cytogenetic Risk, and Platelet Count

Post Allogeneic Stem Cell Transplant Outcomes Following Response to Hypomethylating Agent Therapy in Myelodysplastic Syndromes Are Predicted By Persistent International Prognostic Scoring System-Molecular Risk

Post-Transplant Cyclophosphamide Eliminates Disparity in GvHD-Free, Relapse-Free Survival and Overall Survival between 8/8 Matched and 7/8 Mismatched Unrelated Donor Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies

Patient-Reported Outcomes of BMT CTN 1703: A Randomized Phase III Study for Gvhd Prophylaxis - a Quality of Life Evaluation

Large-Scale Post-Transplant TCR Deep Sequencing Reveals a Major T Cell Diversity Bottleneck with Post-Transplant Cyclophosphamide with Implications for Both Efficacy and Toxicity: Results of the BMT CTN 1801 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only